How much profit has Laboratorios Farmaceuticos ROVI made this year?
Laboratorios Farmaceuticos ROVI has made 160.07 M EUR this year.
In 2024, Laboratorios Farmaceuticos ROVI's profit amounted to 160.07 M EUR, a -6.03% increase from the 170.34 M EUR profit recorded in the previous year.
YEAR | NET INCOME (undefined EUR) |
---|---|
2028e | 388.24 |
2027e | 333.96 |
2026e | 262.04 |
2025e | 194.58 |
2024e | 160.07 |
2023 | 170.34 |
2022 | 199.67 |
2021 | 153.08 |
2020 | 61.06 |
2019 | 39.27 |
2018 | 17.9 |
2017 | 17.24 |
2016 | 26.09 |
2015 | 19.81 |
2014 | 24.12 |
2013 | 23 |
2012 | 19.5 |
2011 | 18.1 |
2010 | 24.6 |
2009 | 20.1 |
2008 | 23.5 |
2007 | 15 |
2006 | 10.9 |
2005 | 4.1 |
2004 | 14.5 |
3 years
5 years
10 years
25 Years
Max
Gain insights into Laboratorios Farmaceuticos ROVI, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Laboratorios Farmaceuticos ROVI from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Laboratorios Farmaceuticos ROVI’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of Laboratorios Farmaceuticos ROVI. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into Laboratorios Farmaceuticos ROVI’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing Laboratorios Farmaceuticos ROVI’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Laboratorios Farmaceuticos ROVI’s growth potential.
Date | Laboratorios Farmaceuticos ROVI Revenue | Laboratorios Farmaceuticos ROVI EBIT | Laboratorios Farmaceuticos ROVI Net Income |
---|---|---|---|
2028e | 1.3 B undefined | 463.34 M undefined | 388.24 M undefined |
2027e | 1.25 B undefined | 458.67 M undefined | 333.96 M undefined |
2026e | 1.08 B undefined | 370.86 M undefined | 262.04 M undefined |
2025e | 896.72 M undefined | 273.42 M undefined | 194.58 M undefined |
2024e | 816.82 M undefined | 223.52 M undefined | 160.07 M undefined |
2023 | 829.51 M undefined | 220.25 M undefined | 170.34 M undefined |
2022 | 817.7 M undefined | 255.85 M undefined | 199.67 M undefined |
2021 | 648.68 M undefined | 183.07 M undefined | 153.08 M undefined |
2020 | 419.96 M undefined | 78.77 M undefined | 61.06 M undefined |
2019 | 381.31 M undefined | 43.18 M undefined | 39.27 M undefined |
2018 | 303.2 M undefined | 17.46 M undefined | 17.9 M undefined |
2017 | 275.65 M undefined | 19.01 M undefined | 17.24 M undefined |
2016 | 265.17 M undefined | 28.3 M undefined | 26.09 M undefined |
2015 | 246.01 M undefined | 21.84 M undefined | 19.81 M undefined |
2014 | 238.05 M undefined | 27.43 M undefined | 24.12 M undefined |
2013 | 217.6 M undefined | 25.4 M undefined | 23 M undefined |
2012 | 201.9 M undefined | 21.7 M undefined | 19.5 M undefined |
2011 | 184.7 M undefined | 19 M undefined | 18.1 M undefined |
2010 | 158.6 M undefined | 26 M undefined | 24.6 M undefined |
2009 | 141.8 M undefined | 25.5 M undefined | 20.1 M undefined |
2008 | 127.5 M undefined | 28.3 M undefined | 23.5 M undefined |
2007 | 100.7 M undefined | 18.4 M undefined | 15 M undefined |
2006 | 105 M undefined | 13.4 M undefined | 10.9 M undefined |
2005 | 82.6 M undefined | 3.3 M undefined | 4.1 M undefined |
2004 | 63.7 M undefined | 3.5 M undefined | 14.5 M undefined |
Revenue | EBIT | Net Income | |
---|---|---|---|
2004 | 63.7 M EUR | 3.5 M EUR | 14.5 M EUR |
2005 | 82.6 M EUR | 3.3 M EUR | 4.1 M EUR |
2006 | 105 M EUR | 13.4 M EUR | 10.9 M EUR |
2007 | 100.7 M EUR | 18.4 M EUR | 15 M EUR |
2008 | 127.5 M EUR | 28.3 M EUR | 23.5 M EUR |
2009 | 141.8 M EUR | 25.5 M EUR | 20.1 M EUR |
2010 | 158.6 M EUR | 26 M EUR | 24.6 M EUR |
2011 | 184.7 M EUR | 19 M EUR | 18.1 M EUR |
2012 | 201.9 M EUR | 21.7 M EUR | 19.5 M EUR |
2013 | 217.6 M EUR | 25.4 M EUR | 23 M EUR |
2014 | 238.05 M EUR | 27.43 M EUR | 24.12 M EUR |
2015 | 246.01 M EUR | 21.84 M EUR | 19.81 M EUR |
2016 | 265.17 M EUR | 28.3 M EUR | 26.09 M EUR |
2017 | 275.65 M EUR | 19.01 M EUR | 17.24 M EUR |
2018 | 303.2 M EUR | 17.46 M EUR | 17.9 M EUR |
2019 | 381.31 M EUR | 43.18 M EUR | 39.27 M EUR |
2020 | 419.96 M EUR | 78.77 M EUR | 61.06 M EUR |
2021 | 648.68 M EUR | 183.07 M EUR | 153.08 M EUR |
2022 | 817.7 M EUR | 255.85 M EUR | 199.67 M EUR |
2023 | 829.51 M EUR | 220.25 M EUR | 170.34 M EUR |
2024e | 816.82 M EUR | 223.52 M EUR | 160.07 M EUR |
2025e | 896.72 M EUR | 273.42 M EUR | 194.58 M EUR |
2026e | 1.08 B EUR | 370.86 M EUR | 262.04 M EUR |
2027e | 1.25 B EUR | 458.67 M EUR | 333.96 M EUR |
2028e | 1.3 B EUR | 463.34 M EUR | 388.24 M EUR |
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the Laboratorios Farmaceuticos ROVI's sales revenue. A higher gross margin percentage indicates that the Laboratorios Farmaceuticos ROVI retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the Laboratorios Farmaceuticos ROVI's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the Laboratorios Farmaceuticos ROVI's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Laboratorios Farmaceuticos ROVI's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Laboratorios Farmaceuticos ROVI. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Laboratorios Farmaceuticos ROVI's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Laboratorios Farmaceuticos ROVI Gross margin | Laboratorios Farmaceuticos ROVI Profit margin | Laboratorios Farmaceuticos ROVI EBIT margin | Laboratorios Farmaceuticos ROVI Profit margin |
---|---|---|---|
2028e | 59.35 % | 35.7 % | 29.91 % |
2027e | 59.35 % | 36.58 % | 26.63 % |
2026e | 59.35 % | 34.28 % | 24.22 % |
2025e | 59.35 % | 30.49 % | 21.7 % |
2024e | 59.35 % | 27.36 % | 19.6 % |
2023 | 59.35 % | 26.55 % | 20.53 % |
2022 | 63.55 % | 31.29 % | 24.42 % |
2021 | 59.32 % | 28.22 % | 23.6 % |
2020 | 57.46 % | 18.76 % | 14.54 % |
2019 | 56.31 % | 11.33 % | 10.3 % |
2018 | 57.58 % | 5.76 % | 5.9 % |
2017 | 60.77 % | 6.9 % | 6.25 % |
2016 | 57.75 % | 10.67 % | 9.84 % |
2015 | 60.54 % | 8.88 % | 8.05 % |
2014 | 60.27 % | 11.52 % | 10.13 % |
2013 | 60.98 % | 11.67 % | 10.57 % |
2012 | 62.61 % | 10.75 % | 9.66 % |
2011 | 62.43 % | 10.29 % | 9.8 % |
2010 | 60.4 % | 16.39 % | 15.51 % |
2009 | 67.28 % | 17.98 % | 14.17 % |
2008 | 72.31 % | 22.2 % | 18.43 % |
2007 | 68.22 % | 18.27 % | 14.9 % |
2006 | 71.81 % | 12.76 % | 10.38 % |
2005 | 71.91 % | 4 % | 4.96 % |
2004 | 68.6 % | 5.49 % | 22.76 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2004 | 68.6 % | 5.49 % | 22.76 % |
2005 | 71.91 % | 4 % | 4.96 % |
2006 | 71.81 % | 12.76 % | 10.38 % |
2007 | 68.22 % | 18.27 % | 14.9 % |
2008 | 72.31 % | 22.2 % | 18.43 % |
2009 | 67.28 % | 17.98 % | 14.17 % |
2010 | 60.4 % | 16.39 % | 15.51 % |
2011 | 62.43 % | 10.29 % | 9.8 % |
2012 | 62.61 % | 10.75 % | 9.66 % |
2013 | 60.98 % | 11.67 % | 10.57 % |
2014 | 60.27 % | 11.52 % | 10.13 % |
2015 | 60.54 % | 8.88 % | 8.05 % |
2016 | 57.75 % | 10.67 % | 9.84 % |
2017 | 60.77 % | 6.9 % | 6.25 % |
2018 | 57.58 % | 5.76 % | 5.9 % |
2019 | 56.31 % | 11.33 % | 10.3 % |
2020 | 57.46 % | 18.76 % | 14.54 % |
2021 | 59.32 % | 28.22 % | 23.6 % |
2022 | 63.55 % | 31.29 % | 24.42 % |
2023 | 59.35 % | 26.55 % | 20.53 % |
2024e | 59.35 % | 27.36 % | 19.6 % |
2025e | 59.35 % | 30.49 % | 21.7 % |
2026e | 59.35 % | 34.28 % | 24.22 % |
2027e | 59.35 % | 36.58 % | 26.63 % |
2028e | 59.35 % | 35.7 % | 29.91 % |
The profit margins of Laboratorios Farmaceuticos ROVI represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Laboratorios Farmaceuticos ROVI's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Evaluating Laboratorios Farmaceuticos ROVI's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Laboratorios Farmaceuticos ROVI's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
When Laboratorios Farmaceuticos ROVI’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Laboratorios Farmaceuticos ROVI has made 160.07 M EUR this year.
The profit has increased by -6.03% compared to last year fallen
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
Laboratorios Farmaceuticos ROVI publishes its earnings in the form of quarterly or annual reports.
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
The profits of Laboratorios Farmaceuticos ROVI are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
You can learn more about the earnings of Laboratorios Farmaceuticos ROVI by reviewing the quarterly or annual reports or following the company presentations.
Over the past 12 months, Laboratorios Farmaceuticos ROVI paid a dividend of 1.29 EUR . This corresponds to a dividend yield of about 1.76 %. For the coming 12 months, Laboratorios Farmaceuticos ROVI is expected to pay a dividend of 1.69 EUR.
The current dividend yield of Laboratorios Farmaceuticos ROVI is 1.76 %.
Laboratorios Farmaceuticos ROVI pays a quarterly dividend. This is distributed in the months of August, August, August, August.
Laboratorios Farmaceuticos ROVI paid dividends every year for the past 21 years.
For the upcoming 12 months, dividends amounting to 1.69 EUR are expected. This corresponds to a dividend yield of 2.3 %.
Laboratorios Farmaceuticos ROVI is assigned to the 'Health' sector.
To receive the latest dividend of Laboratorios Farmaceuticos ROVI from 7/10/2024 amounting to 1.104 EUR, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.
The last dividend was paid out on 7/10/2024.
In the year 2023, Laboratorios Farmaceuticos ROVI distributed 0.956 EUR as dividends.
The dividends of Laboratorios Farmaceuticos ROVI are distributed in EUR.
Our stock analysis for Laboratorios Farmaceuticos ROVI Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laboratorios Farmaceuticos ROVI Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.